Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

More Than Half Of Erectile Dysfunction Drugs Sold Online In Japan Fakes

This article was originally published in PharmAsia News

Executive Summary

A survey revealed that over 55 percent of erectile dysfunction drugs sold over the internet targeting Japanese customers are counterfeits. Conducted from December 2008 to April 2009, the survey is a joint project of four drug makers of Viagra (sildenafil), Levitra (vardenafil) and Cialas (tadalafil): Pfizer, Bayer Yakuhin, Eli Lilly Japan and Nippon Shinyaku. The companies analyzed drug samples ordered from 30 websites that are based in domestic locations and 30 sites in Thailand targeting Japanese customers. The results show that the majority of the counterfeits are imports from Thailand, accounting for 67.8 percent, and fake ED drugs purchased inside Japan account for 43.6 percent. The quality of the counterfeits also vary; some contain more or less active ingredients and others have no active ingredients at all. (Click here for more - Japanese language

Latest Headlines
See All
UsernamePublicRestriction

Register

SC070728

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel